BRCA2 does not mediate BER [45] and, therefore, it is unlikely that, by targeting BRCA2 (which involves DNA repair pathways other than BER), cancer cells would be sensitized to a drug that requires BER for its toxicity. Here, BRCA2 is linked to cancer.